Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07283705 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT07283705: Recruiting Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT07283705 is a Phase 2 study that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 60 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07283705, a Phase 2 study, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
To find out if the combination of BMS-986504 plus neoadjuvant/adjuvant chemotherapy and surgery (Cohort 1) or BMS-986504 plus standard of care chemotherapy (Cohorts 2 and 3) can help to control pancreatic cancer.
Interventions
- DRUG Gemcitabine
- DRUG mFOLFIRINOX
- DRUG Nab-paclitaxel
- DRUG BMS-986504
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2026-05-18 |
| Est. Completion | 2031-10-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07283705
The ClinicalTrials.gov registry entry for NCT07283705 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Gemcitabine is the first listed.
NCT07283705 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07283705 about?
NCT07283705 is a clinical study titled "A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer". To find out if the combination of BMS-986504 plus neoadjuvant/adjuvant chemotherapy and surgery (Cohort 1) or BMS-986504 plus standard of care chemotherapy (Cohorts 2 and 3) can help to control pancreatic cancer.
What is the current status of trial NCT07283705?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2026-05-18. Estimated completion is 2031-10-01.
What interventions are being tested in trial NCT07283705?
The interventions under investigation include: Gemcitabine (DRUG), mFOLFIRINOX (DRUG), Nab-paclitaxel (DRUG), BMS-986504 (DRUG).
Who is sponsoring clinical trial NCT07283705?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.